Author:
González Juan Marcos,Doan Justin,Gebben David J.,Boeri Marco,Fishman Mayer
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference42 articles.
1. de Groot S, Redekop WK, Versteegh MM, Sleijfer S, Oosterwijk E, Kiemeney LALM, et al. Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Qual Life Res. 2018;27:115–24.
2. National Cancer Institute. SEER cancer statistics factsheets: kidney and renal pelvis cancer. Available at:
https://seer.cancer.gov/statfacts/html/kidrp.html
. Accessed 8 Jan 2018.
3. Geynisman DM, Hu JC, Liu L, Tina Shih YC. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. Clin Genitourin Cancer. 2015;13:e93–100.
4. Xu JX, Maher VE, Zhang L, Tang S, Sridhara R, Ibrahim A, et al. FDA approval summary: nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis. Oncologist. 2017;22:311–7.
5. Bedke J, Gauler T, Grünwald V, Hegele A, Herrmann E, Hinz S, et al. Systemic therapy in metastatic renal cell carcinoma. World J Urol. 2017;35:179–88.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献